期刊文献+

硫氧还原蛋白过氧化物酶1在肝癌组织中表达的临床意义

Expression of peroxiredoxin 1 in hepatocellular carcinoma and its clinical significance
下载PDF
导出
摘要 目的探讨硫氧还原蛋白过氧化物酶1(peroxiredoxin 1,Prx1)在肝癌组织及癌旁组织中表达的意义。方法随机选取人肝癌组织及癌旁组织标本80例,石蜡包埋切片后采用免疫组化SP方法染色及RT-PCR法观察Prx1蛋白和mRNA在癌组织及癌旁组织中的表达水平,分析Prx1蛋白差异性表达的意义及与临床病理的关系。结果Prx1主要在肝癌组织及癌旁组织胞质中表达。Prx1在肝癌组织中的蛋白和mRNA表达水平明显高于癌旁组织(P〈0.05)。Prx1的表达与有无血管侵犯(P〈0.01)和TNM分级有关(P〈0.05),而与患者年龄、性别、肿瘤大小、肿瘤数目、包膜是否完整及甲胎蛋白(AFP)水平无关(P〉0.05)。结论Prx1在肝癌组织及癌旁组织中表达水平上调,参与了肝癌的发生、发展。 Objective To investigate the levels of peroxiredoxin 1 ( Prx 1 ) in hepatocellular carcinoma (HCC) and adjacent tissue and its clinical significance. Methods A total of 80 samples of human HCC and adjacent tissues were randomly selected for paraffin embedding and sectioning. The resultant slices were used for immunohistochemical staining SP and RT - PCR to observe the levels of Prx 1 protein and mRNA in HCC and adjacent tissues and analyze the relation- ship between the differential expression of Prx 1 protein and clinical pathological charateristics. Results Prx 1 was mainly expressed in the cytoplasm of HCC and adjacent tissues. The levels of Prx 1 protein and mRNA were remarkably higher in HCC tissues than those in the adjacent tissues ( P 〈 0.01 ). The expression of Prx 1 was associated with vascu- lar invasion ( P 〈 0.01 ) and TNM classification ( P 〈 0.05 ), rather than a patient's age, gender, tumor size and num- ber, intact envelop and alpha fetal protein (AFP) level ( P 〉 0.05 ). Conclusions The expression of Prx I is up - reg- ulated in HCC and adjacent tissues, and Prx 1is involved in pathogenesis of hepatic cancer.
作者 高标 李向农
出处 《徐州医学院学报》 CAS 2017年第1期17-20,共4页 Acta Academiae Medicinae Xuzhou
关键词 肝细胞肝癌 硫氧还原蛋白过氧化物酶1 免疫组织化学 逆转录-聚合酶链反应 hepatocellular carcinoma peroxiredoxin 1 immunohistochemistry reverse transcription - polymerase chain reaction
  • 相关文献

参考文献1

二级参考文献15

  • 1Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
  • 2Liu L,Zhu XD,Wang WQ,et al.Activation of beta-cateninby hypoxia in hepatocellular carcinoma contributes to en-hanced metastatic potential and poor prognosis[J].ClinCancer Res,2010,16(10):2740-2750.
  • 3Huang XY,Huang ZL,Wang L,et al.Herbal compound"Songyou Yin"reinforced the ability of interferon-alfa to in-hibit the enhanced metastatic potential induced by palliativeresection of hepatocellular carcinoma in nude mice[J].BMCCancer,2010,10:580.
  • 4Ellis LM,Reardon DA.Is there really a yin and yang to VEGF-targeted therapies[J].Lancet Oncol,2010,11(9):809-811.
  • 5Ye QH,Qin LX,Forgues M,et al.Predicting hepatitis B vi-rus-positive metastatic hepatocellular carcinomas usinggene expression profiling and supervised machine learning[J].Nat Med,2003,9(4):416-423.
  • 6Shen YC,Hsu C,Chen LT,et al.Adjuvant interferon therapyafter curative therapy for hepatocellular carcinoma(HCC):ameta-regression approach[J].J Hepatol,2010,52(6):889-894.
  • 7Zhang XW,Yan XJ,Zhou ZR,et al.Arsenic trioxide controlsthe fate of the PML-RARalpha oncoprotein by directly bind-ing PML[J].Science,2010,328(5975):240-243.
  • 8Grivennikov SI,Greten FR,Karin M.Immunity,inflamma-tion,and cancer[J].Cell,2010,140(6):883-899.
  • 9Dinarello CA.Anti-inflammatory agents:present and future[J].Cell,2010,140(6):935-950.
  • 10Jacobs EJ.Will an aspirin a day help keep fatal cancer away?[J].Lancet,2011,377(9759):3-4.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部